LGND · Ligand Pharmaceuticals Incorpor
$284.61
-1.61% last session
End-of-day data · close of 2026-09-11
Market cap
$6B
Enterprise value
$6B
Trailing P/E
29.8
Forward P/E
24.2
Dividend yield
—
Beta
0.98
Avg volume
0M
Employees
0K
Daily Change %
-1.61%
5 Days Change
0.86%
10 Days Change
1.39%
30 Days Change
-0.24%
60 Days Change
-8.91%
Month to Day Change
1.33%
Year to Day Change
52.35%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LGND
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-14
Latest call per bank · past 12 months
RBC Capital
Outperform$345
+19.3% vs priceBank of America
Buy$388
+34.1% vs priceCitigroup
Buy$282
-2.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Leerink Partners | Initiates | Outperform | $0.00 → $330 |
| 2026-08-07 | RBC Capital | Maintains | Outperform | $340 → $345 |
| 2026-08-06 | HC Wainwright & Co. | Maintains | Buy | $289 → $358 |
| 2026-08-03 | Oppenheimer | Reiterates | Outperform | $285 → $326 |
| 2026-07-15 | RBC Capital | Maintains | Outperform | $262 → $340 |
| 2026-07-09 | Bank of America | Maintains | Buy | $266 → $388 |
| 2026-07-08 | Stifel | Maintains | Buy | $255 → $332 |
| 2026-05-08 | RBC Capital | Maintains | Outperform | $252 → $262 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.7% below the 50-day MA ($295.62).
- Price vs 200-day MA: Trading 21.6% above the 200-day MA ($234.09).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.40) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($165.41) and high ($322.61).
LGND Price Chart
Loading chart for LGND…
Fundamentals
About Ligand Pharmaceuticals Incorpor
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.